Cargando…

P2X7 receptor antagonist delivery vehicle based on photocrosslinked amphiphilic hybrid gels

We report here a method for the synthesis of a unique hybrid gel system for the sustained delivery of P2X7 receptor (P2X7R) antagonist. P2X7R has been reported as a key mediator in inflammatory processes and controlled delivery of this molecule would be critical for the treatment of inflammatory art...

Descripción completa

Detalles Bibliográficos
Autores principales: Aydin, Derya, Kizilel, Seda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9080578/
https://www.ncbi.nlm.nih.gov/pubmed/35541129
http://dx.doi.org/10.1039/c8ra01460d
_version_ 1784702818908635136
author Aydin, Derya
Kizilel, Seda
author_facet Aydin, Derya
Kizilel, Seda
author_sort Aydin, Derya
collection PubMed
description We report here a method for the synthesis of a unique hybrid gel system for the sustained delivery of P2X7 receptor (P2X7R) antagonist. P2X7R has been reported as a key mediator in inflammatory processes and controlled delivery of this molecule would be critical for the treatment of inflammatory arthritis. The hybrid gel designed here for the sustained delivery of P2X7R antagonists is based on crosslinked hydrophobic styrene-butadiene-styrene (SBS) polymer as a continuous network, where hydrogel particles prepared with hydrophilic poly(ethylene glycol) (PEG) were embedded into this system. PEG hydrogel particle-incorporated SBS gels were characterized through electron microscopy, water contact angle observations, and strong mechanical properties were confirmed through nanoindentation measurements. The release of P2X7R antagonist from these hybrid hydrogel-elastomer system demonstrated a sustained drug release profile up to 28 days at physiological pH, which was not observed in earlier reports. We obtained drug release percentages ranging from 49.72% to 93.04% which indicated the tunability of release through SBS crosslinking and hydrophilic/hydrophobic nature of SBS. This tunability is significant to achieve simultaneous improvements in drug efficacy with reduced side effects. CellTiter-Glo luminescence measurements using human kidney cells revealed that these networks are non-toxic and highly biocompatible with percent cell viabilities of higher than 85%. The approach presented here with crosslinked, amphiphilic and elastic SBS gel systems is not only promising for extended release of P2X7R antagonist but could also allow for incorporation of different molecules so that simultaneous/sequential and extended release profiles for therapeutic molecules could be achieved.
format Online
Article
Text
id pubmed-9080578
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher The Royal Society of Chemistry
record_format MEDLINE/PubMed
spelling pubmed-90805782022-05-09 P2X7 receptor antagonist delivery vehicle based on photocrosslinked amphiphilic hybrid gels Aydin, Derya Kizilel, Seda RSC Adv Chemistry We report here a method for the synthesis of a unique hybrid gel system for the sustained delivery of P2X7 receptor (P2X7R) antagonist. P2X7R has been reported as a key mediator in inflammatory processes and controlled delivery of this molecule would be critical for the treatment of inflammatory arthritis. The hybrid gel designed here for the sustained delivery of P2X7R antagonists is based on crosslinked hydrophobic styrene-butadiene-styrene (SBS) polymer as a continuous network, where hydrogel particles prepared with hydrophilic poly(ethylene glycol) (PEG) were embedded into this system. PEG hydrogel particle-incorporated SBS gels were characterized through electron microscopy, water contact angle observations, and strong mechanical properties were confirmed through nanoindentation measurements. The release of P2X7R antagonist from these hybrid hydrogel-elastomer system demonstrated a sustained drug release profile up to 28 days at physiological pH, which was not observed in earlier reports. We obtained drug release percentages ranging from 49.72% to 93.04% which indicated the tunability of release through SBS crosslinking and hydrophilic/hydrophobic nature of SBS. This tunability is significant to achieve simultaneous improvements in drug efficacy with reduced side effects. CellTiter-Glo luminescence measurements using human kidney cells revealed that these networks are non-toxic and highly biocompatible with percent cell viabilities of higher than 85%. The approach presented here with crosslinked, amphiphilic and elastic SBS gel systems is not only promising for extended release of P2X7R antagonist but could also allow for incorporation of different molecules so that simultaneous/sequential and extended release profiles for therapeutic molecules could be achieved. The Royal Society of Chemistry 2018-05-18 /pmc/articles/PMC9080578/ /pubmed/35541129 http://dx.doi.org/10.1039/c8ra01460d Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by/3.0/
spellingShingle Chemistry
Aydin, Derya
Kizilel, Seda
P2X7 receptor antagonist delivery vehicle based on photocrosslinked amphiphilic hybrid gels
title P2X7 receptor antagonist delivery vehicle based on photocrosslinked amphiphilic hybrid gels
title_full P2X7 receptor antagonist delivery vehicle based on photocrosslinked amphiphilic hybrid gels
title_fullStr P2X7 receptor antagonist delivery vehicle based on photocrosslinked amphiphilic hybrid gels
title_full_unstemmed P2X7 receptor antagonist delivery vehicle based on photocrosslinked amphiphilic hybrid gels
title_short P2X7 receptor antagonist delivery vehicle based on photocrosslinked amphiphilic hybrid gels
title_sort p2x7 receptor antagonist delivery vehicle based on photocrosslinked amphiphilic hybrid gels
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9080578/
https://www.ncbi.nlm.nih.gov/pubmed/35541129
http://dx.doi.org/10.1039/c8ra01460d
work_keys_str_mv AT aydinderya p2x7receptorantagonistdeliveryvehiclebasedonphotocrosslinkedamphiphilichybridgels
AT kizilelseda p2x7receptorantagonistdeliveryvehiclebasedonphotocrosslinkedamphiphilichybridgels